Pharmacy Compounded Medicines for Patients With Rare Diseases: Lessons Learned From Chenodeoxycholic Acid and Cholic Acid

Yasmin Polak, Bart A. W. Jacobs, E. Marleen Kemper

Research output: Contribution to journalArticleAcademicpeer-review

6 Citations (Scopus)

Abstract

Patients with rare diseases are often confronted with the fact that effective medicines are unavailable or simply not being developed. This situation jeopardizes the health of a large population of vulnerable patients with rare diseases. Pharmacy compounded formulations can provide a safe alternative when authorized treatments are unavailable or unsuitable. Practical guidelines on how to develop and implement pharmacy compounded formulations for patients with rare diseases are limited. The aim of this article is to provide guidance for when and how to apply pharmacy compounded formulations for patients with rare diseases. This is illustrated with two challenging examples: the development and implementation of pharmacy compounding of 1) chenodeoxycholic acid (CDCA) capsules for patients with cerebrotendinous xanthomatosis (CTX) and 2) cholic acid (CA) capsules for patients with rare bile acid synthesis defects (BASD). All critical steps of the development of CDCA and CA capsules are explained and summarized in a practical guideline.
Original languageEnglish
Article number758210
JournalFrontiers in Pharmacology
Volume12
DOIs
Publication statusPublished - 28 Sept 2021

Keywords

  • bile acid synthesis defects
  • cerebrotendinous xanthomathosis
  • chenodeoxycholic acid
  • cholic acid
  • orphan medicines
  • pharmacy compounding
  • rare diseases

Cite this